{"id":16204,"date":"2024-01-08T08:50:42","date_gmt":"2024-01-08T08:50:42","guid":{"rendered":"http:\/\/model1.caplinpoint.net\/?p=16204"},"modified":"2024-01-08T08:52:07","modified_gmt":"2024-01-08T08:52:07","slug":"caplin-steriles-gets-usfda-approval-for-ofloxacin-otic-solution","status":"publish","type":"post","link":"http:\/\/model1.caplinpoint.net\/index.php\/2024\/01\/08\/caplin-steriles-gets-usfda-approval-for-ofloxacin-otic-solution\/","title":{"rendered":"CAPLIN STERILES GETS USFDA APPROVAL FOR OFLOXACIN OTIC SOLUTION"},"content":{"rendered":"\n<p><strong>Chennai, January 08, 2024: Caplin Steriles Limited (Caplin)<\/strong>, a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Otic Solution 0.3%, a generic therapeutic equivalent version of (RLD), FLOXIN Otic Solution of Daiichi Pharmaceuticals Inc.<\/p>\n\n\n\n<p>Ofloxacin Otic Solution 0.3% is used as anti-infective (antibacterial) for otic (ear) use. According to IQVIATM (IMS Health), Ofloxacin Otic Solution 0.3% had US sales of approximately $36 million for the 12-month period ending June 2023.<\/p>\n\n\n\n<div class=\"wp-block-file\"><a target=\"_blank\" href=\"http:\/\/model1.caplinpoint.net\/wp-content\/uploads\/2023\/04\/Press_Release_Ofloxacin_SE.pdf\" class=\"wp-block-file__button\" rel=\"noopener\">Download<\/a><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chennai, January 08, 2024: Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Otic Solution 0.3%, a generic therapeutic equivalent version of (RLD), FLOXIN Otic&#8230; <\/p>\n","protected":false},"author":1,"featured_media":1229,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/16204"}],"collection":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/comments?post=16204"}],"version-history":[{"count":2,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/16204\/revisions"}],"predecessor-version":[{"id":16207,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/posts\/16204\/revisions\/16207"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/media\/1229"}],"wp:attachment":[{"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/media?parent=16204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/categories?post=16204"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/model1.caplinpoint.net\/index.php\/wp-json\/wp\/v2\/tags?post=16204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}